Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06969430 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
A Phase 1 study of Acute Myeloid Leukemia, sponsored by Debiopharm International.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 134
- Enrollment target
- 7
- Study locations
NCT06969430 is a Phase 1 study of Acute Myeloid Leukemia that is actively recruiting participants, run by Debiopharm International. The registered enrollment target is 134 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (17% higher). The trial reports 7 study locations across 7 states.
The verdict
NCT06969430, a Phase 1 study of Acute Myeloid Leukemia, is actively recruiting participants, sponsored by Debiopharm International.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 134 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary purpose of Phase 1 is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development (Dose optimization). The primary objective of Phase 2 is to evaluate the antileukemic activity of Debio 1562M.
Conditions Studied
Interventions
- DRUG Debio 1562M
Study Locations (7)
California
- City of Hope Comprehensive Cancer Center - Duarte
Florida
- Moffitt Cancer Center and Research Institute Hospital - Tampa
Illinois
- University of Chicago - Chicago
Michigan
- START Midwest - Grand Rapids
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
Ohio
- The Ohio Sate University - Columbus
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2025-05-30 |
| Est. Completion | 2031-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06969430
The ClinicalTrials.gov registry entry for NCT06969430 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (17% higher). The listed sponsor is Debiopharm International, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Debio 1562M is the first listed.
NCT06969430 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06969430 about?
NCT06969430 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)". The primary purpose of Phase 1 is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development (Dose optimization). The primary objective of Phase 2 is to evaluate the antileukemic activity of Debio 1562M.
What is the current status of trial NCT06969430?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 134 participants. The study started on 2025-05-30. Estimated completion is 2031-11.
What conditions does trial NCT06969430 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia.
What interventions are being tested in trial NCT06969430?
The interventions under investigation include: Debio 1562M (DRUG).
Who is sponsoring clinical trial NCT06969430?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06969430 being conducted?
This trial has 7 study locations across California, Florida, Illinois, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.